A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease.

By Hiroaki Ito, M. Takazoe, Y. Fukuda, T. Hibi, K. Kusugami, A. Andoh, Takayuki Matsumoto, T. Yamamura, J. Azuma, N. Nishimoto and 3 more. Gastroenterology, 2004

647 citations recorded by the source corpus.

Subfields: Genetics, Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/b8255a74ad9f5a8164dd1255e4d0b9e04a13fb63

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

In Immunology

In Oncology

Citations in the corpus

Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality (2020, neutral): “[42] Ito H , Takazoe M , Fukuda Y , Hibi T , Kusugami K , Andoh A , et al.”
Inflammatory bone loss: pathogenesis and therapeutic intervention (2012, background): “and, at least in high doses, may alleviate the symptoms of Crohn's diseas”
Cytokine Networks in the Pathophysiology of Inflammatory Bowel Disease. (2019, positive): “IL6ST, IL31RA anti-IL6R ameliorates TNBS, Il10 -/- and T cell transfer colitis anti-IL6R (clinical improvement) (Ito et al., 2004)”
Interleukin-6 in aging and chronic disease: a magnificent pathway. (2006, background): “Pilot and full-scale randomized clinical trials are currently being conducted for the treatment of Crohn’s disease (33), rheumatoid arthritis (149), moderately active systemic lupus erythematosus (150), and Castelman’s disease (151,152).”
Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. (2014, background): “Clinical response was reported in treatment of Crohn's disease (Ito et al., 2004).”
Interleukin 6: from bench to bedside (2006, background): “Treatment every 2 weeks was superior to that every 4 weeks”
IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. (2011, background): “Based on the experimental evidence for a key role of IL-6 in chronic intestinal inflammation a clinical pilot study was initiated in patients with active Crohn’s disease [97].”
Directing Transition from Innate to Acquired Immunity: Defining a Role for IL-61 (2005, background): “This is exemplified by the application of the blocking anti-IL-6 receptor Ab MRA (Atlizumab, Tocilizumab), which has proven highly effective in the treatment of rheumatoid arthritis and Crohn’s disease (16, 17).”